english.prescrire.org > Prescrire International > N°115 - April 2011

n°115

April 2011

Issue Contents
Editorial

Free  We want our money back!

p.88
Unnecessary and dangerous expenditure

New Products


Mifamurtide: new adverse effects (New Drug)

p.89
Osteosarcoma: ineffective and harmful

Omalizumab (Update)

p.90-92
A second look in severe persistent asthma: new adverse effects

Omalizumab in children (New Indication)

p.92
A negative risk-benefit balance in severe persistent asthma

Trabectedin and ovarian cancer (New Indication)

p.93
Statistical trickery

INN common-stem: -retin

p.93

Rosuvastatin and primary cardiovascular prevention (New Indication)

p.94
Continue to use pravastatin or simvastatin

Adverse Effects


Free  Bradycardia due to cholinesterase inhibitors: identify adverse effects and take them into account

p.95
A neglected adverse effect

Bisphosphonates and atrial fibrillation: clinical trial data suggest possible link

p.96-97
Vigilance is required

Upper gastrointestinal bleeding and spironolactone

p.98-99
Pharmacovigilance signals

Buflomedil: still too many fatal cardiac and neurological events

p.99
Marketing authorisation finally suspended in France

Drug interactions with cannabis

p.100
Pharmacokinetic and pharmacodynamic interactions

Medically assisted reproduction

p.100
A review of adverse effects in France

Reviews


First-line antiretroviral treatment of HIV-infected children

p.101-104
A choice largely based on adult data

Outlook


Free  New drugs and indications in 2010: inadequate assessment; patients at risk

p.105-110

Free  Drugs to avoid

p.107

Free  Medicines agencies too often under the influence of drug companies

p.108

Free  Finding solutions, along with patients

p.110

Free  Prescrire turns 30

p.112

Masthead


Free  Masthead

p.86

The complete contents of 
this issue of Prescrire International
are available for download by
Prescrire International subscribers.
Certain texts are also available to
non-subscribers for free download,
as indicated. 

 

Subscribe